Literature DB >> 11323428

Mechanism and requirements for bovine papillomavirus, type 1, E1 initiator complex assembly promoted by the E2 transcription factor bound to distal sites.

C M Sanders1, A Stenlund.   

Abstract

DNA replication of papillomavirus requires the viral initiator E1 and the transcription factor E2. Bovine papillomavirus, type 1 (BPV-1), E1, and E2 bind cooperatively as dimers to proximal sites in the viral replicator generating a sequence-specific E1E2-ori complex. This complex is critical for replication and can be converted to a multimeric E1-ori initiator complex by displacement of E2 in the presence of hydrolyzable ATP. However, E2 can function over extended distances, and E2 at a distal position 33 base pairs upstream of the E1-binding site also loads an E1 dimer onto ori. Under these conditions, neither displacement of E2 nor ATP hydrolysis are required for E1-ori formation, consistent with a need for ATP hydrolysis in E2 displacement from E1E2-ori. However, ATP is required for stabilization of the resulting E1-ori complex. These results indicate that BPV (with a proximal E2-binding site) and human papillomaviruses (with distal E2-binding sites) utilize the same general mechanism for E1 loading but suggest that E1E2-ori, which forms preferentially on ori, may perform an additional role in BPV replication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323428     DOI: 10.1074/jbc.M101861200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Inhibition of human papillomavirus DNA replication by an E1-derived p80/UAF1-binding peptide.

Authors:  Michaël Lehoux; Amélie Fradet-Turcotte; Mathieu Lussier-Price; James G Omichinski; Jacques Archambault
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  ATP-dependent minor groove recognition of TA base pairs is required for template melting by the E1 initiator protein.

Authors:  Stephen Schuck; Arne Stenlund
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

Review 3.  The E1 proteins.

Authors:  Monika Bergvall; Thomas Melendy; Jacques Archambault
Journal:  Virology       Date:  2013-09-10       Impact factor: 3.616

4.  E1-mediated recruitment of a UAF1-USP deubiquitinase complex facilitates human papillomavirus DNA replication.

Authors:  Michaël Lehoux; David Gagnon; Jacques Archambault
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

5.  Nuclear accumulation of the papillomavirus E1 helicase blocks S-phase progression and triggers an ATM-dependent DNA damage response.

Authors:  Amélie Fradet-Turcotte; Fanny Bergeron-Labrecque; Cary A Moody; Michaël Lehoux; Laimonis A Laimins; Jacques Archambault
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

6.  Replication of bovine papillomavirus type 1 (BPV-1) DNA in Saccharomyces cerevisiae following infection with BPV-1 virions.

Authors:  Kong-Nan Zhao; Ian H Frazer
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Human Papillomavirus Replication Regulation by Acetylation of a Conserved Lysine in the E2 Protein.

Authors:  Yanique Thomas; Elliot J Androphy
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

8.  Nuclear export of human papillomavirus type 31 E1 is regulated by Cdk2 phosphorylation and required for viral genome maintenance.

Authors:  Amélie Fradet-Turcotte; Cary Moody; Laimonis A Laimins; Jacques Archambault
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

9.  Characterization of the minimal DNA binding domain of the human papillomavirus e1 helicase: fluorescence anisotropy studies and characterization of a dimerization-defective mutant protein.

Authors:  S Titolo; K Brault; J Majewski; P W White; J Archambault
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 10.  Recent advances in the search for antiviral agents against human papillomaviruses.

Authors:  Amélie Fradet-Turcotte; Jacques Archambault
Journal:  Antivir Ther       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.